Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioTrove aims to heal losses with $75m IPO

This article was originally published in Clinica

Executive Summary

Genomic analysis specialist BioTrove is looking to combat anticipated operating losses by raising $75m via an IPO of its common shares. The company's net loss has doubled over the past two years - it recorded a net loss of $7.9m in 2005 and a deficit of approximately $16m last year. Despite generating revenue of $4.8m in 2007, the company was weighed down by around $17m of expenses linked to sales and marketing costs and the continued development of its platform technologies. On completion of the IPO, BioTrove will list its shares on the Nasdaq Stock Exchange under the ticker symbol "BTRV".

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel